Without a magic wand, India cannot eliminate TB by 2025

At the end of 50 years of tuberculosis control activities, the disease remains a major health challenge in India. As per new estimates, the number of new cases every year has risen to 2.8 million and mortality is put at 4,80,000 each year. These figures may go up when the national TB prevalence survey is... Continue Reading →

Why is TB bacteria not on WHO’s deadly superbug list?

Of the estimated 10.4 million new tuberculosis cases globally in 2015, nearly 0.5 million estimated cases were multidrug-resistant (MDR) TB cases. Another nearly one million were resistant to rifampicin drug alone. India accounted for 2.84 million new cases in 2015, of which 79,000 had MDR-TB. There were 1.4 million TB deaths worldwide in 2015. For... Continue Reading →

Pilot testing of bedaquiline drug on TB patients to start soon

A pilot programme to test the toxicity, particularly cardio-toxicity, of bedaquiline drug (used for combating multidrug-drug resistant TB) in the Indian population, assess its ability to achieve culture conversion and check the operational feasibility of using the drug to treat MDR-TB patients would start in India by the end of this month or on World... Continue Reading →

Clinical trials on child-friendly bedaquiline MDR-TB drug for children initiated

“Before the BPCA [Best Pharmaceuticals for Children Act] and the PREA [Paediatric Research Equity Act] became law, more than 80 per cent of the drugs approved [by FDA] for adult use were being used for children, even though the safety and effectiveness had not been established in the latter. Today that number has been reduced... Continue Reading →

Child-friendly, first-line TB combination drugs will be available in 2016: Dr. Mel Spigelman

Dr. Mel Spigelman, President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance) is regarded as one of the world’s leading experts in tuberculosis and TB drug development. He was instrumental in forging key organisational partnerships and building the pipeline of TB drug candidates when he was the Director of... Continue Reading →

Is the new TB drug already being misused?

Bedaquiline was the first TB drug to be discovered in more than 40 years, and the first one specifically for multi-drug resistant TB (MDR-TB). MDR-TB arises when the M. tuberculosis bacteria become resistant to two commonly used first-line TB drugs — isonazid and rifampicin. But less than six months after FDA approved the drug under... Continue Reading →

Create a website or blog at WordPress.com

Up ↑

%d bloggers like this: